Mesoblast (NASDAQ:MESO) Raised to “Hold” at StockNews.com

Mesoblast (NASDAQ:MESO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Several other research firms have also commented on MESO. Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and upped their target price for the company from $4.00 to $11.00 in a research note on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research note on Thursday, June 20th.

Mesoblast Stock Performance

Shares of MESO opened at $6.37 on Tuesday. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $8.66. The stock has a fifty day moving average of $6.86 and a two-hundred day moving average of $5.78. The company has a market capitalization of $727.31 million, a PE ratio of -5.69 and a beta of 3.48.

Institutional Trading of Mesoblast

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after acquiring an additional 1,663 shares during the last quarter. Perkins Coie Trust Co acquired a new position in shares of Mesoblast in the 2nd quarter valued at about $68,000. Pine Valley Investments Ltd Liability Co purchased a new stake in shares of Mesoblast during the 2nd quarter worth about $80,000. Rathbones Group PLC acquired a new stake in Mesoblast during the 2nd quarter worth approximately $95,000. Finally, Chapin Davis Inc. raised its holdings in Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after buying an additional 5,000 shares during the period. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.